Iovance Biotherapeutics, Inc. (IOVA) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Net income in fiscal 2025 was -$391M, a net margin of -148.4%; the best year in this period was 2016 with -$53M.
Over the twelve months to September 30, 2026, revenue was $379M and net income -$221M.
Free cash flow was -$336M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 547% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $379M | $264M | $164M | $1M | — | — | — | — | $0 | $0 | $0 |
| Gross profit | $202M | $90M | $71M | $156000 | — | — | — | — | — | — | — |
| Operating income | -$230M | -$403M | -$395M | -$461M | -$399M | -$343M | -$262M | -$207M | -$128M | -$93M | -$54M |
| Net income | -$221M | -$391M | -$372M | -$444M | -$396M | -$342M | -$260M | -$198M | -$124M | -$92M | -$53M |
| EPS (diluted) | $-0.50 | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | $-1.27 | $-1.41 | $-1.85 |
| R&D | $242M | $300M | $276M | $333M | $295M | $259M | $202M | $166M | $100M | $72M | $27M |
| Revenue growth | — | +60.6% | +13699.0% | — | — | — | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$190M | -$302M | -$353M | -$362M | -$293M | -$228M | -$205M | -$159M | -$101M | -$79M | -$33M |
| Capital spending | -$26M | -$34M | -$11M | -$22M | -$20M | -$38M | -$47M | -$7M | -$1M | -$1M | -$2M |
| Free cash flow | -$216M | -$336M | -$364M | -$384M | -$313M | -$266M | -$252M | -$166M | -$102M | -$80M | -$34M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $47M | $62M | $110M | $63M | $84M | $70M | $41M | $24M | $20M | $12M | $19M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $297M | $324M | $280M | $472M | $504M | $629M | $307M | $469M | $145M | $107M |
| Debt | — | $49M | $58M | $76M | $85M | $72M | $52M | $12M | — | — | — |
| Equity | — | $699M | $710M | $585M | $500M | $622M | $656M | $299M | $466M | $145M | $167M |
| Total assets | — | $913M | $910M | $780M | $664M | $777M | $768M | $345M | $481M | $155M | $172M |
| Shares (diluted) | 434M | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 53.2% | 34.3% | 43.2% | 13.1% | — | — | — | — | — | — | — |
| Operating margin | -60.8% | -153.1% | -240.9% | -38735.0% | — | — | — | — | — | — | — |
| Net margin | -58.2% | -148.4% | -226.8% | -37345.4% | — | — | — | — | — | — | — |
| FCF margin | -57.0% | -127.6% | -221.9% | -32305.3% | — | — | — | — | — | — | — |
| ROIC | — | -53.6% | -51.0% | -69.2% | -68.2% | -49.4% | -29.2% | -52.6% | -21.7% | -50.4% | -25.4% |
| ROE | — | -56.0% | -52.4% | -75.9% | -79.2% | -55.0% | -39.5% | -66.1% | -26.5% | -63.3% | -31.7% |
Frequently asked questions
What is Iovance Biotherapeutics’s annual revenue?
$264M in fiscal 2025 and $379M over the twelve months to September 30, 2026.
How much profit does Iovance Biotherapeutics make?
Net income was -$391M in fiscal 2025 (net margin -148.4%).
Is Iovance Biotherapeutics’s revenue growing?
Yes: revenue rose 60.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.